Suppr超能文献

SARS-CoV-2 关切变异株部分逃避 COVID-19 恢复期患者和疫苗接种者的体液但不逃避 T 细胞反应。

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees.

机构信息

Department of Viroscience, Erasmus MC; Rotterdam, the Netherlands.

Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment; Bilthoven, the Netherlands.

出版信息

Sci Immunol. 2021 May 25;6(59). doi: 10.1126/sciimmunol.abj1750.

Abstract

The emergence of SARS-CoV-2 variants harboring mutations in the spike (S) protein has raised concern about potential immune escape. Here, we studied humoral and cellular immune responses to wild type SARS-CoV-2 and the B.1.1.7 and B.1.351 variants of concern in a cohort of 121 BNT162b2 mRNA-vaccinated health care workers (HCW). Twenty-three HCW recovered from mild COVID-19 disease and exhibited a recall response with high levels of SARS-CoV-2-specific functional antibodies and virus-specific T cells after a single vaccination. Specific immune responses were also detected in seronegative HCW after one vaccination, but a second dose was required to reach high levels of functional antibodies and cellular immune responses in all individuals. Vaccination-induced antibodies cross-neutralized the variants B.1.1.7 and B.1.351, but the neutralizing capacity and Fc-mediated functionality against B.1.351 was consistently 2- to 4-fold lower than to the homologous virus. In addition, peripheral blood mononuclear cells were stimulated with peptide pools spanning the mutated S regions of B.1.1.7 and B.1.351 to detect cross-reactivity of SARS-CoV-2-specific T cells with variants. Importantly, we observed no differences in CD4 T-cell activation in response to variant antigens, indicating that the B.1.1.7 and B.1.351 S proteins do not escape T-cell-mediated immunity elicited by the wild type S protein. In conclusion, this study shows that some variants can partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, but S-specific CD4 T-cell activation is not affected by the mutations in the B.1.1.7 and B.1.351 variants.

摘要

SARS-CoV-2 变体在刺突(S)蛋白中携带突变的出现引起了人们对潜在免疫逃逸的关注。在这里,我们研究了 121 名接受 BNT162b2 mRNA 疫苗接种的医护人员(HCW)中针对野生型 SARS-CoV-2 以及关注的 B.1.1.7 和 B.1.351 变体的体液和细胞免疫反应。23 名 HCW 从轻度 COVID-19 疾病中康复,在单次接种后表现出高水平的 SARS-CoV-2 特异性功能性抗体和病毒特异性 T 细胞的回忆反应。在单次接种后,在血清阴性的 HCW 中也检测到了特异性免疫反应,但所有个体都需要接种第二剂才能达到高水平的功能性抗体和细胞免疫反应。疫苗诱导的抗体交叉中和了 B.1.1.7 和 B.1.351 变体,但中和能力和 Fc 介导的对 B.1.351 的功能与同源病毒相比始终低 2-4 倍。此外,用跨越 B.1.1.7 和 B.1.351 突变 S 区的肽池刺激外周血单核细胞,以检测 SARS-CoV-2 特异性 T 细胞与变体的交叉反应性。重要的是,我们没有观察到对变体抗原的 CD4 T 细胞激活的差异,表明 B.1.1.7 和 B.1.351 S 蛋白不会逃避由野生型 S 蛋白引起的 T 细胞介导的免疫。总之,这项研究表明,一些变体可以部分逃避 SARS-CoV-2 感染或 BNT162b2 接种诱导的体液免疫,但 B.1.1.7 和 B.1.351 变体中的突变不会影响 S 特异性 CD4 T 细胞的激活。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55ff/9268159/40b24db846c6/sciimmunol.abj1750-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验